How Jardiance Protects Kidney Function
Jardiance (empagliflozin), an SGLT2 inhibitor, slows kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). It reduces the risk of kidney failure, doubling of serum creatinine, or death from kidney or cardiovascular causes by about 28% compared to placebo in trials like EMPA-KIDNEY.[1] This effect holds even in non-diabetic CKD patients with estimated glomerular filtration rate (eGFR) as low as 20 mL/min/1.73 m².
Mechanism Behind the Kidney Benefits
Jardiance blocks sodium-glucose cotransporter 2 in the kidney's proximal tubule, lowering intraglomerular pressure and hyperfiltration—a key driver of CKD worsening. It also reduces proteinuria, inflammation, and fibrosis while promoting erythropoietin production for better tissue oxygenation.[2] These actions provide nephroprotection independent of blood sugar control.
Evidence from Key Clinical Trials
- EMPA-REG OUTCOME: In 7,020 type 2 diabetes patients, Jardiance cut new-onset or worsening nephropathy by 39%.[3]
- EMPA-KIDNEY (2022): Across 6,609 CKD patients (half without diabetes), it lowered major kidney disease progression or CV death risk by 28% (HR 0.72).[1]
- EMPEROR-Reduced: In heart failure patients, it slowed eGFR decline by 1.25 mL/min/1.73 m² per year.[4]
FDA expanded labels in 2023 to include CKD treatment regardless of diabetes or albuminuria levels.
Does It Harm Kidneys? Acute Risks and Monitoring
Jardiance rarely worsens kidney function long-term but carries acute risks:
- Volume depletion from diuresis can drop eGFR temporarily (usually <10%), resolving with hydration.[5]
- Acute kidney injury occurs in <1% of users, higher in dehydrated or low-eGFR starters (<45 mL/min).[6]
- Contraindicated if eGFR <20 mL/min (polycystic kidney disease) or on dialysis; start at 10 mg daily and monitor eGFR at 4 weeks, then periodically.
No increased risk of chronic decline in trials.
Who Benefits Most and When to Use It
Strongest effects in patients with:
- eGFR 20-90 mL/min and albuminuria >200 mg/g.
- Type 2 diabetes plus CVD or CKD.
- Heart failure with reduced ejection fraction.
Guidelines (ADA, KDIGO) recommend it as first-line for CKD with proteinuria, often combined with ACE inhibitors/ARBs.[7]
Comparisons to Other SGLT2 Inhibitors
| Drug | Kidney Risk Reduction (Major Events) | Key Trial | Unique Notes |
|------|--------------------------------------|-----------|--------------|
| Jardiance (empagliflozin) | 28-39% | EMPA-KIDNEY, EMPA-REG | Broadest CKD label |
| Farxiga (dapagliflozin) | 39% | DAPA-CKD | Similar; also polycystic kidney OK |
| Invokana (canagliflozin) | 30% | CREDENCE | Diabetes-only CKD label |
All class effects, but Jardiance has most non-diabetic CKD data.[8]
Sources
[1]: NEJM - EMPA-KIDNEY
[2]: Nature Reviews Nephrology
[3]: NEJM - EMPA-REG
[4]: NEJM - EMPEROR-Reduced
[5]: Jardiance Prescribing Information (Boehringer Ingelheim)
[6]: FDA Label Update
[7]: KDIGO 2022 Guidelines
[8]: DrugPatentWatch - SGLT2 Patent Expirations